Page 182 - Read Online
P. 182

Page 8 of 8                                                    Ding et al. Hepatoma Res 2018;4:12  I  http://dx.doi.org/10.20517/2394-5079.2018.07


                   carcinoma. Hepatology 2015;62:1190-200.
               11.  Dutta R. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther 2017;173:106-17.
               12.  Jing X, Tian ZB, Kong XJ, Ding XL. Evolving research in the relationship between beta2-glycoprotein I and liver diseases. J Genet Mol
                   Cell Biol 2015;2:1-3.
               13.  Stefas I, D’Angeac AD, Morel-Baccard C, Seigneurin JM, Zarski JP, Martin M, Cerutti M, Bossy JP, Missé D, Graafland H, Veas F.
                   Hepatitis B virus Dane particles bind to human plasma apolipoprotein H. Hepatology 2001;33:207-17.
               14.  Gao YH, Wang D, Shi Y, Tang TY, Piao YF, Yang HY. Studies on the association between beta-2- glycoprotein I and hepatotropis of
                   hepatitis B virus. Chin J Hepatoma 2006;14:569-71.
               15.  Gao P, Wang X, Qu L, Shi Y, Yang H. A possible receptor for beta 2 glycoprotein I on the membrane of hepatoma cell line smmc7721.
                   Chin Med J 2003;116:1308-11.
               16.  Gao PJ, Gao YH, Liu YW, Tan Y. The receptor for beta(2)GPI on membrane of hepatocellular carcinoma cell line SMMC-7721 is annexin
                   II. World J Gastroenterol 2007;13:3364-8.
               17.  Agar C, Mörgelin M, Monk SD, van Os G, Levels JH, de Laat B, Urbanus RT, Herwald H, van der Poll T, Meijers JC. β2-glycoprotein I:
                   a novel component of innate immunity. Blood 2011;117:6939-47.
               18.  Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular
                   carcinoma. Gut Microbes 2014;5:441-5.
               19.  Lin A, Zhao H, Zhang Y, Han Q, Zhang C, Tian Z, Zhang J. TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in
                   hepatocellular carcinoma (HCC) cells. Oncoimmunology 2015;5:e1074376.
               20.  Wang Y, Yan W, Xiao D, Zeng Z, Ouyang Y, Huang L, Cai J, Zeng X, Chen YJ, Liu A. CXC195 suppresses proliferation and
                   inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-kB and
                   MAPK pathway. Biochem Biophys Res Commun 2015;456:373.
               21.  Szabo G, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010;28:737-44.
               22.  Lai FB, Jing YY, Yu GF, Han ZP, Yang X, Zeng JX, Zhang HJ, Shi RY, Li XY, Pan XR, Li R, Zhao QD, Wu MC, Zhang P, Liu JF,
                   Wei LX. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α
                   pathway. Cancer Letters 2016;378:131-41.
               23.  Dolcet X, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005;446:475-82.
               24.  Yu Yang, Feng R, Sheng Bi. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J
                   Cancer Res Clin Oncol 2011;137:947-52.
   177   178   179   180   181   182   183   184   185   186   187